Skip to search formSkip to main contentSkip to account menu

recombinant antihemophilic factor VIII

Known as: recombinant factor viii, rfviii 
National Institutes of Health

Related topics

Related topics

9 relations

Narrower (6)

Antihemophilic Factor, Human RecombinantHumate-PKogenateOctocog alfa
Antihemophilic Factor, Human Recombinant 1 UNT InjectionAntihemophilic Factor, Human Recombinant 1 UNT Injection [Recombinate]

Broader (1)

Factor VIII

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
BAY 94‐9027 is a B‐domain‐deleted recombinant factor VIII (rFVIII) with site‐specific attachment of poly(ethylene glycol) that… 
Highly Cited
2014
Highly Cited
2014
Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.
The effect of recombinant factor VIII (rFVIII) brand on inhibitor development was investigated in all 407 severe hemophilia A… 
Highly Cited
2013
Highly Cited
2013
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial.
Safety and pharmacokinetics (PK) of recombinant von Willebrand factor (rVWF) combined at a fixed ratio with recombinant factor… 
Highly Cited
2013
Highly Cited
2013
Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and…
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of… 
Highly Cited
2011
Highly Cited
2011
BAX 855, a PEGylated rFVIII product with prolonged half-life
Summary A longer acting recombinant FVIII is expected to serve patients’ demand for a more convenient prophylactic therapy. We… 
Highly Cited
2009
Highly Cited
2009
Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and…
Summary.  BDDrFVIII is a B‐domain deleted recombinant factor VIII (rFVIII) product for haemophilia A. Manufacture uniquely… 
Highly Cited
2007
Highly Cited
2007
Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A
Background: Most patients with severe hemophilia A suffer from a profoundly compromised hemostatic response. In addition to both… 
Review
2001
Review
2001
Production processes of licensed recombinant factor VIII preparations.
The state-of-the-art treatment for hemophilia A is replacement therapy with recombinant factor VIII (rFVIII) made possible by… 
Highly Cited
2000
Highly Cited
2000
Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
Summary To add an increased level of safety to antihemophilic factor replacement therapy, a full-length, recombinant Factor VIII… 
Highly Cited
1997
Highly Cited
1997
A Multicenter Pharmacosurveillance Study for the Evaluation of the Efficacy and Safety of Recombinant Factor VIII in the Treatment of Patients with Hemophilia A
Summary In this open multicenter study the safety and efficacy of recombinant factor VIII (rFVIII) was assessed in 39 previously… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)